Recent Updates
Recently added Catalysts
RCKT Positive Sentiment

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Tuesday, October 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rocket Pharmaceuticals has secured a strategic credit facility of up to $150 million from Hercules Capital. This agreement is expected to enhance Rocket's financial position and provide necessary capital to support its ongoing initiatives. The funding will aid in advancing the company's efforts in genetic medicines for rare diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Secures a credit facility of up to $150 million.
  • Strengthens financial position for future projects.
  • Provides access to additional capital for execution.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
8%
average across 7 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
RP-L102
Phase 2 · Fanconi Anemia Complementation Group A

Full Press Release Details

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket’s financial position and provides access to additional capital to support executi

Frequently Asked Questions

What is the amount of the credit facility secured?

Rocket Pharmaceuticals secured a credit facility of up to $150 million.

Who is the credit facility from?

The credit facility is from Hercules Capital, Inc.

What will the funding support?

The funding will support Rocket's initiatives in genetic medicines.

How does this facility affect Rocket's financial position?

The facility strengthens Rocket's financial position by providing additional capital.

ShareAdd on Google
Tags: RCKT Rocket Pharmaceuticals Hercules Capital credit facility genetic medicines biotechnology
Last updated: Oct 6, 2026

Biotech snapshot

Cash runway
$284M liquidity · $13M/mo burn
~20 mo
Low dilution risk
Lead asset
RP-L102Phase 2
Fanconi Anemia Complementation Group A →

Catalyst track record

+38%
best trade around RCKT's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for RCKT.

See every catalyst's timing & PoA →